BAM
KLRS

Belpointe Asset Management’s Kalaris Therapeutics KLRS Stock Holding History

Belpointe Asset Management’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$163K Hold
40,000
– – 0.01% 1088
2026
Q1 		$231K Hold
40,000
– – 0.01% 957
2025
Q4 		$338K Hold
40,000
– – 0.01% 791
2025
Q3 		$231K Buy
+40,000
New +$132K 0.01% 882

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Belpointe Asset Management's KLRS Position: Q2 2026 in Review

Belpointe Asset Management held its Kalaris Therapeutics (KLRS) position steady in Q2 2026 at 40,000 shares worth $163K. The position accounts for 0.01% of the portfolio, ranked #1088.

Belpointe Asset Management first reported a position in KLRS in Q3 2025 and has held it in 4 quarters since. The position peaked at $338K in Q4 2025. 56 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • Belpointe Asset Management held 40,000 shares of Kalaris Therapeutics worth $163K as of Q2 2026.
  • Belpointe Asset Management left its Kalaris Therapeutics share count unchanged in Q2 2026.
  • Kalaris Therapeutics made up 0.01% of Belpointe Asset Management's portfolio in Q2 2026, its #1088 holding.
  • Belpointe Asset Management first reported a position in Kalaris Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Belpointe Asset Management's Kalaris Therapeutics position peaked at $338K in Q4 2025.
  • 56 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Belpointe Asset Management's 13F filing for Q2 2026, filed 31 Jul 2026.